Kodiak Sciences Inc. (NASDAQ: KOD)

Kodiak Sciences Inc. is a biotechnology company that discovers and develops therapeutics for retinal diseases.

The company uses its proprietary Antibody Biopolymer Conjugate (ABC) platform to create molecules with extended ocular half life and improved durability.

Its lead product candidate tarcocimab tedromer also known as Zenkuda or KSI 301 is an anti VEGF therapy built on the ABC platform.

Kodiak also advances two additional bispecific candidates KSI 501 and KSI 101 that target IL 6 and VEGF for diseases such as wet age related macular degeneration diabetic retinopathy retinal vein occlusion and macular edema secondary to inflammation.

The company’s pipeline includes early stage programs that aim to treat glaucoma and geographic atrophy using the ABCD platform which extends the technology to conjugate small molecule drugs.

Kodiak Sciences Inc. is headquartered in Palo Alto California and operates a dedicated commercial scale manufacturing facility called Ursus in partnership with Lonza.

Kodiak Sciences Inc. has not yet generated product revenue because its therapeutic candidates remain in clinical development.

The company funds its research and development activities through public and private equity offerings.

It may also receive financial support from collaboration agreements government grants or licensing arrangements.

Until a product receives regulatory approval and reaches commercial sale the primary source of cash is capital raised from investors.

The manufacturing agreement with Lonza for the Ursus facility does not generate revenue but supports future commercial supply.

The company has also accessed non dilutive financing through government research contracts and milestone payments from partnership agreements.

Kodiak Sciences Inc. competes in the retinal therapeutics market where the standard of care consists of intravitreal anti VEGF agents.

Leading products include Avastin Eylea Eylea HD Vabysmo Lucentis and their biosimilars.

Vabysmo is a bispecific antibody that targets VEGF and angiopoietin 2 and offers extended dosing intervals.

Eylea HD provides a higher concentration formulation that allows dosing up to every 16 weeks in many patients.

Numerous other companies pursue gene therapy stem cell transplant medical devices and additional biosimilar approaches for diabetic retinopathy retinal vein occlusion and wet age related macular degeneration.

Kodiak differentiates itself through its ABC platform which creates drug antibody conjugates with a prolonged ocular half life of approximately 20 days for tarcocimab.

This extended half life enables less frequent dosing while maintaining therapeutic exposure.

The platform also supports high drug antibody ratio designs that can deliver multiple active agents over time.

These scientific advantages aim to reduce treatment burden improve durability and potentially deliver disease modifying effects beyond VEGF inhibition.

The company also benefits from its integrated manufacturing capabilities which allow control over product quality and supply chain reliability.

Kodiak Sciences Inc. intends to serve patients who suffer from retinal vascular diseases and inflammatory ocular conditions.

Its product candidates are designed for individuals with diabetic retinopathy retinal vein occlusion wet age related macular degeneration and macular edema secondary to inflammation.

The expected customers include retina specialists ophthalmology clinics hospitals and managed care organizations that administer intravitreal injections.

The company does not disclose specific customer names in its filing.